CA-ARGONAUT-MANUF-SVCS
Argonaut Manufacturing Services (“Argonaut”), a leading contract development and manufacturing organization serving the biopharma and life sciences industries, announced today the completion of a $45 million financing to support its new drug product fill / finish expansion. This expansion in Carlsbad, CA, underway since early 2023, includes a new dedicated facility with a state-of-the-art isolator-based filling line that more than quadruples Argonaut’s existing drug product fill / finish capacity and augments existing vial filling capabilities with the ability to pre-fill syringes and cartridges for clinical and commercial supply. Argonaut expects to have fully validated the facility and all equipment in 2025.
The financing was led by NewVale Capital, a growth equity fund focused on innovative pharmaceutical and life science services businesses, with participation from existing majority investor Telegraph Hill Partners, and other current investors.
Wayne Woodard, founder and CEO of Argonaut, commented: “Argonaut is uniquely positioned to address the manufacturing challenges that biopharma innovators face related to sterile fill / finish of complex and high-value drug products. We remain laser focused on leveraging our experienced team’s commitment to flexibility and client satisfaction while prioritizing quality and compliance. The recent commitment from NewVale Capital and the continued support of Telegraph Hill Partners paves a straight path to capacity expansion and fulfillment of our mission to become the world’s best Drug Product Manufacturing solutions provider for our clients.”
“We are thrilled to partner with Telegraph Hill to support the experienced team at Argonaut, building upon their strong foundation,” said Todd Holmes, Managing Partner of NewVale Capital. “For years, small- and medium-sized biopharma companies have struggled to find reliable, high-quality fill / finish capabilities from providers that prioritize their molecules. With this capital infusion, we can further enable Argonaut’s mission that no innovator, regardless of size, should be waitlisted behind larger pharma or be forced to compromise on quality when trying to bring critical therapies to patients.”
Argonaut’s FDA-registered facilities are compliant with 21 CFR parts 210, 211, and 820 and offer highly flexible and scalable solutions for a broad range of biopharmaceuticals including monoclonal antibodies, proteins, peptides, oligonucleotides, and small molecules. Additionally, Argonaut maintains an ISO 13485:2016 certification to produce drug-device combination products. Argonaut’s quality systems have been successfully audited by many biopharma customers and global regulatory agencies including the FDA and PMDA.
“The recent consolidation in the aseptic fill / finish market has highlighted the need for additional capacity to ensure patients have uninterrupted access to critical life-saving and life-extending therapies,” stated Chris Duffy, SVP/GM of Biopharma Services at Argonaut. “Our deep expertise in fill / finish, coupled with our planned expansion will help address this need for our clients and we remain ready to take on new projects.”
RBC Capital Markets LLC served as exclusive placement agent to Argonaut.
About Argonaut Manufacturing Services
Argonaut Manufacturing Services is an FDA-registered cGMP contract development and manufacturing organization (CDMO) dedicated to providing custom manufacturing and supply chain solutions for biopharmaceutical and diagnostic companies. Aseptic drug fill / finish capabilities feature state-of-the-art automated equipment for high-yield filling of sterile injectable drugs including biologics, peptides, small molecules, and vaccines. Diagnostic manufacturing capabilities include proprietary lyophilization technology and a spectrum of kitting capabilities. Projects are supported with full analytical quality control services including warehousing and global shipping logistics. Serving innovators in the biopharma, life science, and molecular diagnostics industries, Argonaut provides a wide range of flexible solutions for diverse outsourcing needs. For more information, visit: www.argonautms.com.
About Telegraph Hill Partners
Founded in 2001, Telegraph Hill Partners invests in life science, medical device, and healthcare technology companies. For more information, visit: www.telegraphhillpartners.com.
About NewVale Capital
Founded in 2022, NewVale Capital is a growth equity firm that focuses on supporting the next generation of life science services companies. The firm invests in proven, revenue-generating services businesses across the life science ecosystem that are helping to bring medicines to patients. For more information, visit: www.newvalecapital.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240305644445/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OCP Announces Date of Second Quarter and First Half 2025 Earnings19.9.2025 14:30:00 CEST | Press release
OCP S.A. (“OCP” or the “Company”), a global leader in the fertilizer industry, will release its second quarter and first half 2025 results on Friday, September 26, 2025. The results will be available to holders of the Company’s bonds, qualified institutional buyers, securities analysts and market makers on the OCP Intralinks portal from 11:00 a.m. EDT, 4:00 p.m. Morocco and London time (GMT+1). OCP senior management will host a conference call to discuss second quarter and first half 2025 results at 12:00 p.m. EDT, 5:00 p.m. Morocco and London time (GMT+1) on Friday, September 26, 2025, for holders of the Company’s bonds, qualified institutional buyers, securities analysts and market makers. Eligible parties that have not already registered for access to the Intralinks portal may do so by contacting the Investor Relations Department by emailing g.laraki@ocpgroup.ma. About OCP OCP is a global leader in the fertilizer industry, backed by almost a century’s production history. OCP has exc
GCCA Concrete in Life Global Photography Competition Launches19.9.2025 14:00:00 CEST | Press release
Tens of thousands of entries expected, focusing on concrete's essential role Overall winner of the free-to-enter competition will receive top prize of $10,000 USD With category prizes of $2,500 USD across each theme This year’s Concrete in Life, a popular global photography competition which celebrates the essential role of concrete across the world, has been officially launched. Now in its 7th year, the competition which receives tens of thousands of entries every year from every corner of the world, highlights the sustainability, versatility, beauty and durable presence of the world’s most used material after water. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250919202417/en/ Overall Winner, Concrete in Life 2024/25, Venice Beach Skating by Henrik Hagerup, Venice Beach, Los Angeles, USA Run by the Global Cement and Concrete Association (GCCA), the competition is open to everyone - professionals, amateurs, or anyone with
European Commission (EC) Approves Henlius and Organon’s BILDYOS® (denosumab) and BILPREVDA® (denosumab), Biosimilars to PROLIA (denosumab) and XGEVA (denosumab), Respectively19.9.2025 12:00:00 CEST | Press release
Shanghai Henlius Biotech, Inc. (2696.HK), and Organon (NYSE: OGN) today announced the European Commission (EC) has granted marketing authorization for BILDYOS® (denosumab) injection 60 mg/mL and BILPREVDA® (denosumab) injection 120 mg/1.7 mL,biosimilars to PROLIA (denosumab) and XGEVA (denosumab), respectively, for all indications of the reference products.1,2 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250919502394/en/ “The EC approvals of BILDYOS and BILPREVDA mark a pivotal moment in expanding access to essential bone care treatments for millions of Europeans, particularly women, who are disproportionately affected by osteoporosis,” said Nico Van Hoecke, Head, International Commercial at Organon.3,4 “These biosimilars may offer additional treatment options across several therapeutic areas associated with bone loss, including osteoporosis, and reflect Organon’s commitment to advancing women’s health through access to im
Cluster Reply Supports Riverty’s AI-first Strategy for Omnichannel,Human-centric Customer Service19.9.2025 11:15:00 CEST | Press release
Cluster Reply, the Reply company specialised in digital platform solutions leveraging Microsoft technologies, has partnered with fintech company Riverty to accelerate the rollout of a pioneering customer service platform – delivered in record time of just 100 days. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250919101836/en/ The initiative is part of Riverty’s broader strategy to become a leader in AI-powered financial services. The new solution empowers Riverty to deliver efficient, empathetic customer support across all channels while creating a robust foundation for future AI-driven automation. The initiative is part of Riverty’s broader strategy to become a leader in AI-powered financial services. The new solution empowers Riverty to deliver efficient, empathetic customer support across all channels while creating a robust foundation for future AI-driven automation. The platform leverages Microsoft Dynamics 365 Custom
L&T Technology Services Joins the MIT Media Lab to Collaborate on AI-led Innovations19.9.2025 10:30:00 CEST | Press release
With access to world-class research and breakthrough problem-solving opportunities, LTTS will explore next-gen technologies in Mobility, Sustainability and Tech L&T Technology Services (BSE: 540115, NSE: LTTS), a global leader in AI, Digital & ER&D Consulting Services, today announced a multi-year membership agreement with the MIT Media Lab, one of the world’s most prestigious research institutions. As a consortium Lab Member, LTTS intends to explore next-generation advancements in artificial intelligence (AI), underscoring its commitment to driving transformational innovation in Mobility, Sustainability and Tech. As part of the agreement, LTTS will engage in active discussions and information exchange with the Media Lab’s unique cross-disciplinary ecosystem that brings together researchers, innovators and industry leaders. The collaboration not only emphasizes practical AI innovation but also accelerates technology-driven advancements by linking LTTS’ expertise in AI and engineering w
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom